-+ 0.00%
-+ 0.00%
-+ 0.00%
Molecular Partners says first MP0712 patient dosing underway in Phase 1/2a trial for DLL3 radiotherapy candidate
Share
Listen to the news
Molecular Partners says first MP0712 patient dosing underway in Phase 1/2a trial for DLL3 radiotherapy candidate
  • Molecular Partners flagged initial Phase 1/2a data for MP0712 in the coming months, with broader safety and efficacy results targeted for 2027.
  • MP0712, a 212Pb-labeled DLL3 radiotherapeutic partnered with Orano Med, has begun dosing patients in a US multicenter study.
  • South Africa’s NuMeRI launched compassionate-use work on an alternate DLL3 Radio-DARPin using a 177Lu/225Ac theranostic pair, labeled MP0714.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060100OMX_____CNEWS_EN_GNW9757132_en) on July 06, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending